XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2

Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Net Sales and Segment Contribution for Each Reportable Segment

Net sales and segment contribution for each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):

			Wound & Surgical						Regenerative Medicine						Corporate & Other						Consolidated
Net sales			$	66,873					$	—					$	816					$	67,689
Cost of sales			11,159						—						1,029						12,188
Selling, general and administrative expense			35,531						—						17,944						53,475
Research and development expense			1,680						4,273						—						5,953
Amortization of intangible assets			—						—						175						175
Segment contribution			$	18,503					$	(4,273)
Investigation, restatement and related expense																					3,001
Operating loss																					$	(7,103)
Supplemental information
Depreciation expense			$	451					$	36					$	344					$	831
Share-based compensation			$	1,945					$	347					$	80					$	2,372

Net sales and segment contribution by each reportable segment for the three months ended September 30, 2021 were as follows (in thousands):

			Wound & Surgical						Regenerative Medicine						Corporate & Other						Consolidated
Net sales			$	62,138					$	76					$	860					$	63,074
Cost of sales			8,924						16						1,189						10,129
Selling, general and administrative expense			32,104						1,285						12,900						46,289
Research and development expense			1,423						2,945						—						4,368
Amortization of intangible assets			—						—						193						193
Segment contribution			$	19,687					$	(4,170)
Investigation, restatement and related expense																					3,170
Operating loss																					$	(1,075)
Supplemental information
Depreciation expense			$	511					$	34					$	378					$	923
Share-based compensation			$	1,435					$	322					$	2,054					$	3,811

Net sales and segment contribution by each reportable segment for the nine months ended September 30, 2022 were as follows (in thousands):

			Wound & Surgical						Regenerative Medicine						Corporate & Other						Consolidated
Net sales			$	191,297					$	—					$	2,169					$	193,466
Cost of sales			31,126						—						2,821						33,947
Selling, general and administrative expense			108,256						—						50,582						158,838
Research and development expense			6,068						11,361						—						17,429
Amortization of intangible assets			—						—						519						519
Segment contribution			$	45,847					$	(11,361)
Investigation, restatement and related expense																					8,771
Operating loss																					$	(26,038)
Supplemental information
Depreciation expense			$	1,364					$	120					$	1,065					$	2,549
Share-based compensation			$	5,609					$	910					$	4,279					$	10,798

Net sales and segment contribution by each reportable segment for the nine months ended September 30, 2021 were as follows (in thousands):

			Wound & Surgical						Regenerative Medicine						Corporate & Other						Consolidated
Net sales			$	172,401					$	16,584					$	2,221					$	191,206
Cost of sales			25,646						3,652						3,232						32,530
Selling, general and administrative expense			87,392						11,127						46,772						145,291
Research and development expense			4,080						8,690						—						12,770
Amortization of intangible assets			—						—						647						647
Segment contribution			$	55,283					$	(6,885)
Investigation, restatement and related expense																					8,304
Operating loss																					$	(8,336)
Supplemental information
Depreciation expense			$	1,172					$	213					$	2,005					$	3,390
Share-based compensation			$	3,827					$	1,147					$	6,141					$	11,115

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration